Use: To reduce the risk of sustained estimated eGFR decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Usual Adult Dose for Metabolic Dysfunction-Associated Steatohepatitis Wegovy injection: Initial dose (weeks 1 through 4): 0.25 mg subcutaneously once a week Dose escalation: Weeks 5 through 8: 0.5 mg subcutaneously once a week Weeks 9 through 12: 1 mg subcutaneously once a week Weeks 13 through 16: 1.7 mg subcutaneously once a week If 2.4 mg is not tolerated: 1.7 mg subcutaneously once a week
If pain worsens or persists beyond 48 to 72 hours, contact your GP or diabetes specialist nurse for assessment
Like other GLP-1 medications, compounded semaglutide with glycine is contraindicated for patients with a history of medullary thyroid carcinoma, MEN2 (multiple endocrine neoplasia type 2) syndrome, pancreatitis, and gallbladder issues
Common Mistakes To Avoid Some of the most frequent transition mistakes include: Skipping the washout period, which may increase nausea Starting tirzepatide too high, especially if stepping off a high semaglutide dose Assuming similar milligram amounts mean similar potency Titrating too quickly Changing doses without medical supervision Following a structured plan helps avoid these issues
When using Ozempic to treat diabetes, weight loss is a common side effect
Johnson et al., 2007, 2008)
